Back to Awarded Treatment Trials


Awarded Trial: 02-STN-008-2

Grant ID

02-STN-008-2

Illness

Schizophrenia

Primary Drug/Intervention

Amoxapine

Primary Dosage

N/A

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Kapur

Sample Size

40

Duration of Study Period for Each Subject

N/A

Outcome Measurements

N/A

Results

Amoxapine is an off-patent antidepressant that is thought to have antipsychotic properties at certain doses. Forty patients with schizophrenia were randomized to receive amoxapine (up to 250 mg/day) or risperidone (up to 5mg/day) for 6 weeks. Thirty-nine patients completed the study. Amoxapine was equivalent to risperidone for positive, negative and depressive symptoms. Amoxapine produced fewer extrapyramidal side effects and less elevation of prolactin than risperidone. Amoxapine may be an attractive alternative to newer antipsychotics because it is very in expensive.

Publication

Apiquian R, Fresan A, Ulloa RE, de la Fuente-Sandoval C, Herrera-Estrella M, Vazquez A, Nicolini H, Kapur S. Amoxapine as an atypical antipsychotic: a comparative study vs. risperidone. Neuropsychopharmacology. 2005 Dec;30(12):2236-44.

Link

http://www.ncbi.nlm.nih.gov/pubmed/15956984

PI Name

Shitij Kapur

Degree

MD

Center

Centre for Addiction and Mental Health

Institution

Clarke Institute

Address

250 College Street

City or Town

Toronto

State or Province

Ontario

Zip or Postal Code

M5T 1RB

Country

Canada

Email Address

kapur@clarke-inst.on.ca